REGN insider transaction filings
REGENERON PHARMACEUTICALS, INC. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen REGN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Option exercise (M): 12,282 @ $381.92 · Tax withholding (F): 9,019 @ $830.15 · Option exercise (M): 12,282 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Fenimore Christopher R. — EVP Finance CFO | Option exercise (M): 6,283 @ $381.92 · Tax withholding (F): 4,599 @ $813.47 · Option exercise (M): 6,283 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Zoghbi Huda Y — Director | Option exercise (M): 800 @ $376.69 · Sale (S): 800 @ $800 · Option exercise (M): 800 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Guarini Kathryn — Director | Option exercise (M): 400 @ $719.37 · Sale (S): 400 @ $800 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | RYAN ARTHUR F — Director | Sale (S): 200 @ $650.15 | EDGAR |
| 2026-05-04 | 4 | RYAN ARTHUR F — Director | Sale (S): 5 @ $701.76 · Sale (S): 15 @ $702.46 · Sale (S): 24 @ $703.46 · Sale (S): 15 @ $704.28 · Sale (S): 14 @ $705.56 · Sale (S): 7 @ $706.74 · +6 more | EDGAR |
| 2026-04-03 | 4 | RYAN ARTHUR F — Director | Sale (S): 1 @ $771.32 · Sale (S): 3 @ $772.76 · Sale (S): 8 @ $773.59 · Sale (S): 8 @ $774.58 · Sale (S): 14 @ $775.58 · Sale (S): 13 @ $776.62 · +3 more | EDGAR |
| 2026-03-03 | 4 | RYAN ARTHUR F — Director | Sale (S): 7 @ $777.46 · Sale (S): 2 @ $778.30 · Sale (S): 5 @ $779.69 · Sale (S): 3 @ $780.69 · Sale (S): 2 @ $781.21 · Sale (S): 2 @ $782.62 · +7 more | EDGAR |
| 2026-02-23 | 4 | Zoghbi Huda Y — Director | Option exercise (M): 1,638 @ $376.69 · Sale (S): 49 @ $774.68 · Sale (S): 50 @ $775.50 · Sale (S): 53 @ $778.47 · Sale (S): 208 @ $779.55 · Sale (S): 331 @ $780.45 · +7 more | EDGAR |
| 2026-02-11 | 4 | Pitofsky Jason — SVP Controller | Option exercise (M): 1,000 @ $492 · Sale (S): 20 @ $775.95 · Sale (S): 521 @ $776.43 · Sale (S): 391 @ $777.51 · Sale (S): 563 @ $778.35 · Sale (S): 205 @ $779.56 · +7 more | EDGAR |
| 2026-02-11 | 4 | RYAN ARTHUR F — Director | Sale (S): 1 @ $775.63 · Sale (S): 10 @ $776.59 · Sale (S): 57 @ $777.56 · Sale (S): 12 @ $778.53 · Sale (S): 5 @ $779.41 · Sale (S): 1 @ $780.09 · +7 more | EDGAR |
| 2026-01-08 | 4 | Bassler Bonnie L — Director | Option exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Guarini Kathryn — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Bassler Bonnie L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Zoghbi Huda Y — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Schenkein David P — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Thompson Craig B. — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | GOLDSTEIN JOSEPH L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | SING GEORGE L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | COLES N ANTHONY — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | POON CHRISTINE A — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | RYAN ARTHUR F — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | BROWN MICHAEL S — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, Director | Option exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, Director | Option exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | SING GEORGE L — Director | Option exercise (M): 9,212 @ $520.01 · Tax withholding (F): 6,188 @ $774.03 · Option exercise (M): 9,212 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | MURPHY ANDREW J — EVP Research | Tax withholding (F): 4,229 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | McCourt Marion — EVP Commercial | Tax withholding (F): 1,021 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | Van Plew Daniel P — EVP & General Mgr, Industrial | Tax withholding (F): 2,552 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, Director | Option exercise (M): 146,815 @ $555.67 · Tax withholding (F): 131,874 @ $701.51 · Option exercise (M): 146,815 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, Director | Option exercise (M): 172,723 @ $555.67 · Tax withholding (F): 155,145 @ $701.51 · Option exercise (M): 172,723 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Pitofsky Jason — VP Controller | Grant/award (A): 2,064 @ $0 · Tax withholding (F): 989 @ $712.94 · Grant/award (A): 2,261 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | MURPHY ANDREW J — EVP Research | Grant/award (A): 3,715 @ $0 · Tax withholding (F): 1,699 @ $712.94 · Grant/award (A): 18,315 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Fenimore Christopher R. — EVP Finance CFO | Grant/award (A): 3,027 @ $0 · Tax withholding (F): 992 @ $712.94 · Grant/award (A): 14,924 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | McCourt Marion — EVP Commercial | Grant/award (A): 2,476 @ $0 · Tax withholding (F): 1,336 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Van Plew Daniel P — EVP & General Mgr, Industrial | Grant/award (A): 3,715 @ $0 · Tax withholding (F): 1,906 @ $712.94 · Grant/award (A): 18,315 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Grant/award (A): 2,476 @ $0 · Tax withholding (F): 1,396 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Bassler Bonnie L — Director | Option exercise (M): 760 @ $371.40 · Sale (S): 760 @ $750 · Option exercise (M): 760 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Option exercise (M): 14,450 @ $555.67 · Tax withholding (F): 12,686 @ $736.77 · Option exercise (M): 14,450 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | Pitofsky Jason — VP Controller | Sale (S): 431 @ $651.43 | EDGAR |
| 2025-10-31 | 4 | MURPHY ANDREW J — EVP Research | Option exercise (M): 35,000 @ $555.67 · Tax withholding (F): 32,490 @ $648.82 · Gift (G): 1,538 @ $0 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2025-10-31 | 4 | POON CHRISTINE A — Director | Option exercise (M): 6,500 @ $520.01 · Sale (S): 650 @ $652.68 · Sale (S): 2,735 @ $653.50 · Sale (S): 1,915 @ $654.42 · Sale (S): 100 @ $655.10 · Sale (S): 712 @ $656.50 · +4 more | EDGAR |
Recent 8-K events — REGENERON PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-08 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-01-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2025-08-01 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=REGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →